P0043 - Sertraline in treatment of depression, panic disorder, OCD and PTSD at dailly hospital, psychiatric clinic Sarajevo university

Abstract

Background and Aims:

Sertraline is an antidepressant of the SSRI class, and shared common side effects and contraindications with other members of SSRI class.

Aim of this study is to show how Sertraline is effective in treatment of distinguish psychiatric disorders, observing side effects as well.

Methods:

This prospective study covered 30 patients, randomly selected at Psychiatric Clinic University of Sarajevo.

SCID-I and CGI was used as instruments. Dose vary related to clinical state (25-150 mg/day)

Results:

Out of total number of patients (30); 22 (73.3%) are female and 8 (267%) males with disorders as follows: Depression (667%),Panic Disorder and PTSD (33% each) and OCD (6,7%).

Starting Sertraline dose was 25 mg/day, which is increased in 90% of cases to 50mg/day, and 100 mg/day (6.7%) after one week of treatment resulting with average dose of 52.5 mg/day (average change 27.5). During second follow up there is a further increase of dose to the average of 76.67 mg/day ranging from 25 to 150 mg/day (average 25). Duration of follow up was 3-6 months. 43.3% of patients in our sample were taking concomitant pharmacotherapy in form of anxiolitic and antidepressants.

Conclusion:

Sertraline is significantly effective as therapy for Depression, Panic disorder, OCD. None of the patients reported some side effects from the Sertraline therapy. In 90.0% of cases final evaluation of response was excellent with 10% of very good response to treatment